ENCLAI Daily · Article of the day 29 Sep 2026 · ENCLAI Editorial

PCV13 boosts systemic but not mucosal immunity to pneumococcal serotype 3

NEW MEDICAL STUDY EXPLAINED · 29 SEPTEMBER 2026PCV13 boosts systemic but not mucosalimmunity to pneumococcal serotype 3PubMed 42743942Early-phase /non-randomisedStudy type407participantsLancetMicrobejournal15 Sep 2026publishedIn a nested analysis of the PREVENTING PNEUMO 2 trial, PCV13vaccination significantly increased serum IgG for pneumococcalserotype 3, with a two-fold rise observed in 93 of 139participants.What the study found1Between July 28, 2021, and October 3, 2023, 407 participants wereincluded in the serotype 3 challenge analyses and 243 in the serotype6B challenge analyses.2PCV13 vaccination significantly increased CPS3-specific andCPS6B-specific serum IgG levels at one month compared to baseline,with p-values less than 0.0001 for both.3Only CPS6B-specific IgG was detectable in nasal wash samples at onemonth compared to baseline, with a p-value less than 0.0001.Who it applies toThe study included healthy adults aged18 to 50 years who participated in theparent PREVENTING PNEUMO 2 trial.Participants had received PCV13,PPV23, or placebo in the parent trialand were included in assay-specificanalyses based on sample availability.What it does not establishNasal CPS3-specific IgG was detectedonly after serotype 3 challenge inparticipants with pneumococcalcarriage, indicating low mucosalimmunity. CPS3-specific memory B cellfrequencies declined rapidly aftervaccination.The authors' conclusion“PCV13 vaccination induced systemic humoral immune responses to bothserotypes but they differed in magnitude, duration, and tissuedistribution.”Summary of the published abstract, not medical advice. Read the paper before acting on it.Source: PubMed 42743942 · enclai.net/newsVerify every figure against the source before use; ENCLAI does not guarantee accuracy orcompleteness.
  1. In a nested analysis of the PREVENTING PNEUMO 2 trial, PCV13 vaccination significantly increased serum IgG for pneumococcal serotype 3, with a two-fold rise observed in 93 of 139 participants.
  2. Between July 28, 2021, and October 3, 2023, 407 participants were included in the serotype 3 challenge analyses and 243 in the serotype 6B challenge analyses.
  3. PCV13 vaccination significantly increased CPS3-specific and CPS6B-specific serum IgG levels at one month compared to baseline, with p-values less than 0.0001 for both.
  4. Only CPS6B-specific IgG was detectable in nasal wash samples at one month compared to baseline, with a p-value less than 0.0001.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

In a nested analysis of the PREVENTING PNEUMO 2 trial, PCV13 vaccination significantly increased serum IgG for pneumococcal serotype 3, with a two-fold rise observed in 93 of 139 participants. However, nasal IgG for serotype 3 was detected only after challenge in participants who acquired carriage, suggesting limited mucosal protection.

Who the findings apply to

The study included healthy adults aged 18 to 50 years who participated in the parent PREVENTING PNEUMO 2 trial.

Participants had received PCV13, PPV23, or placebo in the parent trial and were included in assay-specific analyses based on sample availability.

Participants were intranasally challenged with Streptococcus pneumoniae serotype 3 one month after vaccination.

A subgroup of participants was additionally challenged with Streptococcus pneumoniae serotype 6B six months after vaccination.

Why this matters

Pneumococcal serotype 3 remains a common cause of disease despite some direct protection from PCV13. This study assesses whether specific immune responses correlate with protection from experimental carriage. The findings indicate that while systemic responses are robust, the lack of detectable mucosal immunity to serotype 3 may explain reduced protection against carriage acquisition compared to serotype 6B.

What the study found

Between July 28, 2021, and October 3, 2023, 407 participants were included in the serotype 3 challenge analyses and 243 in the serotype 6B challenge analyses.

PCV13 vaccination significantly increased CPS3-specific and CPS6B-specific serum IgG levels at one month compared to baseline, with p-values less than 0.0001 for both.

Only CPS6B-specific IgG was detectable in nasal wash samples at one month compared to baseline, with a p-value less than 0.0001.

A more than two-fold increase in CPS3-specific IgG concentration was seen in 93 (67%) of 139 participants who received PCV13 and 46 (51%) of 91 participants who received PPV23.

A more than two-fold increase in CPS6B-specific IgG concentration was seen in 103 (96%) of 107 participants who received PCV13 and 58 (79%) of 73 participants who received PPV23.

PCV13-induced CPS3-specific memory B cells were associated with protection from serotype 3 carriage acquisition, but their frequency rapidly declined.

What the result does not establish

Nasal CPS3-specific IgG was detected only after serotype 3 challenge in participants with pneumococcal carriage, indicating low mucosal immunity.

CPS3-specific memory B cell frequencies declined rapidly after vaccination.

The study was an exploratory analysis nested within a phase 4 human pneumococcal challenge trial.

The interpretation suggests that low mucosal immunity to serotype 3 might contribute to reduced protection against carriage acquisition, but this is an association rather than a definitive causal mechanism.

Authors’ conclusion

“PCV13 vaccination induced systemic humoral immune responses to both serotypes but they differed in magnitude, duration, and tissue distribution. The low mucosal immunity to Spn3 might contribute to reduced protection against Spn3 carriage acquisition.”

Trial registration

Registered with the ISRCTN registry as ISRCTN15728847. ENCLAI does not hold this registry record, so its details are not shown; follow the link to read it.

NCT04974294

Registered titlePREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) (Pneumo 2)
Registry statusPhase 4, interventional, unknown
Lead sponsorLiverpool School of Tropical Medicine
Registered size516 participants — planned enrolment (estimate). The abstract reports: 407 participants
Where1 site in 1 country (United Kingdom)
Registered primary outcome
  • The rate of experimental pneumococcal colonisation with SPN3 determined by the presence of pneumococcus in nasal wash (NW) by classical culture or molecular methods (time frame: any time point during 23 days following experimental human pneumococcal challenge (EHPC) 1 month after vaccination in…)
  • Start: Jul 2021
  • Primary completion: Jul 2023 (estimated; this date has passed — check the registry)
  • Completion: Dec 2023 (estimated; this date has passed — check the registry)
  • Paper published: Sep 2026
Filled circle: date reached. Open circle: date the registry lists as estimated.

ClinicalTrials.gov record as held by ENCLAI, last updated Jan 2023. The registry status may have changed since; the link shows the current record.

Study and sources

Evaluation of the effect of serotype on pneumococcal conjugate vaccine-induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial

Early-phase / non-randomised trial · Phase 4 · Lancet Microbe · 2026-09-15

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.